The Conversation (0)
Dr. Reddy’s Laboratories Launches Aspirin and Extended-Release Dipyridamole Capsules in the U.S. Market
Dec. 24, 2018 08:33AM PST
Life Science Investing NewsDr. Reddy’s Laboratories (BSE:500124,NSE:DRREDDY,NYSE:RDY), along with its subsidiaries together referred to as “Dr. Reddy’s”, today announced the launch of Aspirin and Extended-Release Dipyridamole Capsules, a therapeutic equivalent generic version of Aggrenox (aspirin and extended-release dipyridamole) Capsules in the United States market from the U.S. Food and Drug Administration (USFDA). As quoted in the press release: …
Dr. Reddy’s Laboratories (BSE:500124,NSE:DRREDDY,NYSE:RDY), along with its subsidiaries together referred to as “Dr. Reddy’s”, today announced the launch of Aspirin and Extended-Release Dipyridamole Capsules, a therapeutic equivalent generic version of Aggrenox (aspirin and extended-release dipyridamole) Capsules in the United States market from the U.S. Food and Drug Administration (USFDA).
As quoted in the press release:
The Aggrenox brand and generic had U.S. sales of approximately $182 million MAT for the most recent twelve months ending in October 2018 according to IMS Health*.
Dr. Reddy’s Aspirin and Extended-Release Dipyridamole Capsules are available in 25 mg/200 mg strength with 60 count bottle size. Aggrenox is a trademark of Boehringer Ingelheim. *IMS National Sales Perspective: Retail and Non-Retail MAT October 2018
RDY-1218-230